Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
(NASDAQ:PSNL) FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate that Personalisā highly sensitive molecular residual disease (MRD) test, NeXT PersonalĀ®, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer (NSCLC) receiving neoadjuvant therapy. The findings, which will be p
Related Questions
How will the positive NeoADAURA trial data affect Personalis' revenue forecasts and stock valuation?
What is the timeline for regulatory approval and commercial rollout of the NeXT PersonalĀ® MRD test in the EGFRāmutated NSCLC market?
How does Personalis' MRD technology compare to competing platforms in terms of sensitivity, adoption by major pharma partners, and potential market share?